Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept dosing regimens in psoriatic arthritis with psoriasis
2005-001533-15Phase 3Completed
- Sponsor
- Wyeth
- Start
- Jul 2005
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of etanercept in plaque psoriasis and psoriatic arthritis (PsA) (2 arms), sponsored by Wyeth. Primary endpoint: Physician Global Assessment clear or almost clear at Week 12. Started Jul 2005; status: completed.
02
Drugs
etanercept
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2005-001533-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001533-15.